Pharming Group reports second quarter and first half 2024 financial results and provides business updateGlobeNewsWire • 08/01/24
Pharming Group to report second quarter and first half 2024 financial results on August 1GlobeNewsWire • 07/18/24
Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European UnionGlobeNewsWire • 05/30/24
Pharming Group reports on results of the 2024 Annual General Meeting of ShareholdersGlobeNewsWire • 05/21/24
Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025GlobeNewsWire • 05/15/24
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact AwardsGlobeNewsWire • 04/24/24
Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?Zacks Investment Research • 04/22/24
Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025GlobeNewsWire • 04/19/24
Pharming Group announces the placement of €100 million convertible bonds due 2029GlobeNewsWire • 04/18/24
Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025GlobeNewsWire • 04/18/24
Pharming announces completion of enrollment in pediatric clinical trial of leniolisibGlobeNewsWire • 04/08/24
Pharming Group to report fourth quarter and full year 2023 financial results on March 14GlobeNewsWire • 02/29/24
Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch updateGlobeNewsWire • 01/08/24
Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)GlobeNewsWire • 12/13/23